Zobrazeno 1 - 10
of 114
pro vyhledávání: '"programmed death protein 1"'
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 5, Pp 382-399 (2024)
Immune checkpoint inhibitors (ICIs) are used to relieve and refuel anti-tumor immunity by blocking the interaction, transcription, and translation of co-inhibitory immune checkpoints or degrading co-inhibitory immune checkpoints. Thousands of small m
Externí odkaz:
https://doaj.org/article/aa781a13d9664f5395153c422423ff77
Autor:
Aviwe Ntsethe, Zekhethelo Alondwe Mkhwanazi, Phiwayinkosi Vusi Dludla, Bongani Brian Nkambule
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 3, Pp 1731-1740 (2024)
Chronic lymphocytic leukemia (CLL) is characterized by dysfunctional B cells. Immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1) are upregulated in patients with CLL and may correlat
Externí odkaz:
https://doaj.org/article/d4799eda6e56452d97842da2362a3e5e
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Background Colorectal cancer (CRC) is one of the most common malignancies worldwide. Immunotherapy targeting the programmed death protein 1(PD-1) and its ligand (PD-L1), is a promising treatment option for many cancers, but has exhibited poo
Externí odkaz:
https://doaj.org/article/6f5d4958e2d046d981df06e308d6166d
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionGastric cancer (GC) complicated by bone marrow metastasis (BMM) and disseminated intravascular coagulation (DIC) represents poor prognosis and most of these patients would die in a few months. Active treatment strategies such as chemother
Externí odkaz:
https://doaj.org/article/e404c900230e4acea48b65659383d7c4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Suxia Geng, Ruohao Xu, Xin Huang, Minming Li, Chengxin Deng, Peilong Lai, Yulian Wang, Ping Wu, Xiaomei Chen, Jianyu Weng, Xin Du
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Hypomethylating agents (HMAs) are widely used in patients with higher-risk MDS not eligible for stem cell transplantation. However, the general response rate by HMAs is lesser than 50% in MDS patients, while the relapse rate is high. Emerging evidenc
Externí odkaz:
https://doaj.org/article/c4f90879820d4bb0a080d4069b6b6fc0
Publikováno v:
Терапевтический архив, Vol 93, Iss 6, Pp 649-660 (2021)
Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) and programmed death protein 1 (PD-1) or its ligand (PD-L1), are a new generation of immuno-oncological drugs that to date have demonstrated efficacy
Externí odkaz:
https://doaj.org/article/1d32c2e173f64b9aa68f053e583c8a20
Publikováno v:
Frontiers in Immunology, Vol 12 (2022)
Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd. Toripalimab is able to bind to PD-1 and block the interaction with its ligan
Externí odkaz:
https://doaj.org/article/15814ad079bc47cda7b7aaa03f0733a4
Autor:
Sandra Schöniger, Bharat Jasani
Publikováno v:
Animals, Vol 12, Iss 19, p 2661 (2022)
The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway mainly attracted attention in immuno-oncology, leading to the development of immune checkpoint therapy. It has, however, much broader importance for tissue physiology
Externí odkaz:
https://doaj.org/article/c4631115ca024b82a961786c6a828cc1
Autor:
Mutiara Indah Sari, Syafruddin Ilyas
Publikováno v:
Diagnostics, Vol 12, Iss 8, p 2004 (2022)
Sepsis is a series of life-threatening organ dysfunction caused by an impaired host response to infection. A large number of molecular studies of sepsis have revealed complex interactions between infectious agents and hosts that result in heterogeneo
Externí odkaz:
https://doaj.org/article/c04b9eeced2248fbaa55664bb48dac6b